Abstract 898P
Background
Oral mucositis (OM) is severe in up to 70% of patients receiving standard chemoradiation (7 weeks of RT and concurrent cisplatin). Cisplatin contributes to the acute toxicity (acute kidney injury, tinnitus, myelosuppression) during treatment but also causes irreversible chronic kidney disease (CKD) in up to 30% of patients in the years following treatment. Two randomized, placebo-controlled, blinded studies, ROMAN (NCT03689712) and GT-201 (NCT02508389), evaluated avasopasem 90mg (AVA) for the reduction of severe OM (SOM, WHO grade 3-4) and both met their primary endpoints.
Methods
The ROMAN phase 3 (ITT N=407) and GT-201 phase 2b trials (ITT placebo and 90 mg N=144) results were aggregated using conventional methods for fixed-effects meta-analysis. In ROMAN, prospectively defined follow-up of serum creatinine (sCr) and estimated glomerular filtration rates (eGFR) were assessed every 3 months for 1 year following 7 weeks of CRT.
Results
The meta-analysis of ROMAN and GT-201 (N=551 [313 AVA/238 PBO]) showed a 19% relative reduction in SOM incidence (52% vs 64%; P=0.0053), 58% relative reduction in SOM duration (median, 8 vs 19 days; P=0.0002), 32% reduction in Grade 4 incidence (22% vs 32%; P=0.0102), and 28% delay in median days to SOM onset (median 50 vs 39 days; P=0.0005). Adverse event frequencies were mostly comparable between treatment groups with a trend towards reduction of certain IMRT- and cisplatin-related toxicities including tinnitus which was reported less with AVA in both studies. At 1-year follow-up, AVA was associated with significant improvements in preservation of eGFR (P=0.0008) and sCr (P=0.006) levels vs PBO. Grade 3+ CKD results through 12 months show 10% AVA vs 20% PBO (relative risk 0.55, P=0.0043).
Conclusions
AVA produced statistically significant, clinically meaningful improvement of SOM vs PBO that was consistent across multiple measures of SOM, with an adverse event profile consistent with expectations for IMRT/cisplatin. At 1-year follow-up, AVA appears to reduce cisplatin-related CKD in the study population.
Clinical trial identification
GTI-4419-301, 13 July 2020 (NCT03689712).
Editorial acknowledgement
Editorial (Sarah Hummasti, PhD) was provided by AOIC, LLC and funded by Galera Therapeutics, Inc.
Legal entity responsible for the study
Galera Therapeutics, Inc.
Funding
Galera Therapeutics, Inc.
Disclosure
N. Dunlap: Financial Interests, Personal, Speaker, Consultant, Advisor: AstraZeneca. C. Anderson: Non-Financial Interests, Personal and Institutional, Speaker, Consultant, Advisor: Galera Therapeutics, Inc. C. Lee: Financial Interests, Personal and Institutional, Research Funding: Bayer, Merck, Decipher Genetics; Financial Interests, Personal and Institutional, Advisory Role: Bayer, Merck, Decipher Genetics; Financial Interests, Personal, Stocks or ownership: Axcend LLC, Kobold Medical LLC. J. Kelley: Financial Interests, Personal and Institutional, Research Funding: Galera Therapeutics, Inc. G. Walker: Financial Interests, Personal, Advisory Role: Galera Therapeutics, Inc.; Financial Interests, Personal and Institutional, Research Funding: Galera Therapeutics, Inc. V. Bar-Ad: Financial Interests, Personal and Institutional, Research Funding: Galera Therapeutics, Inc. D. Miller: Financial Interests, Personal and Institutional, Research Funding: Galera Therapeutics, Inc. V. King: Financial Interests, Personal, Ownership Interest: San Juan Cancer Center; Financial Interests, Personal, Leadership Role: San Juan Cancer Center. A. Peddada: Financial Interests, Personal, Stocks/Shares: Galera Therapeutics, Inc. D. Ciuba: Financial Interests, Personal and Institutional, Research Funding: Galera Therapeutics, Inc. F. Vincent: Financial Interests, Personal and Institutional, Research Funding: Galera Therapeutics, Inc. B. Muzyka: Financial Interests, Institutional, Research Funding: Galera Therapeutics, Inc. A. Gillespie-Twardy: Financial Interests, Personal and Institutional, Research Funding: Galera Therapeutics, Inc. S. Sonis: Financial Interests, Personal, Full or part-time Employment: Primary Endpoint Solutions ; Financial Interests, Personal, Leadership Role: Primary Endpoint Solutions ; Financial Interests, Institutional, Other, Contract work for study: Galera Therapeutics, Inc. E. Kennedy: Financial Interests, Personal, Full or part-time Employment: Galera Therapeutics, Inc.; Financial Interests, Personal, Stocks or ownership: Galera Therapeutics, Inc. D. Saunders: Financial Interests, Personal and Institutional, Research Funding: Galera Therapeutics, Inc.
Resources from the same session
889P - CT-based radiomics models to predict progression in locally advanced head and neck cancer treated with definitive chemoradiation
Presenter: Gema Bruixola
Session: Poster session 12
890P - Real-world survival outcomes and survival risk factors in elderly patients with locally advanced squamous cell carcinoma of the head and neck
Presenter: Nabil Saba
Session: Poster session 12
891P - Changing landscape of head and neck squamous cell carcinoma (HNSCC) treatment and survival in Thailand: A 13-year multicenter retrospective study of 6,319 patients
Presenter: Nuttapong Ngamphaiboon
Session: Poster session 12
892P - Real-world data validation of university of San Diego nomogram for the prediction of benefit of intensive treatment for locoregionally advanced head and neck cancer
Presenter: Javier Caballero Daroqui
Session: Poster session 12
893P - Tumor node stage shift following leukocyte interleukin injection neoadjuvant extends overall survival in treatment-naïve locally advanced oral cavity/soft palate squamous cell carcinoma
Presenter: Jozsef Timar
Session: Poster session 12
894P - Is pathological complete response (PCR) a surrogate endpoint of overall survival in patients with technically unresectable oral cavity cancers? A real-world data study of 900 plus patients
Presenter: Shatabdi Chakraborty
Session: Poster session 12
896P - Efficacy and safety of pembrolizumab with preoperative neoadjuvant chemotherapy in patients with resectable locally advanced head and neck squamous cell carcinomas
Presenter: Kai Wang
Session: Poster session 12
897P - Nanosomal docetaxel lipid suspension (NDLS) or docetaxel based neoadjuvant therapy in Head and neck squamous cell carcinoma: Post hoc analysis of a prospective, randomized study
Presenter: Darshit Shah
Session: Poster session 12
899P - Impact of COVID-19 pandemic on treatment and survival in head and neck squamous cell carcinoma (HNSCC) patients (IMPACCT Study)
Presenter: Berta Vilar Anglada
Session: Poster session 12